How Will the Market React to Genocea Biosciences Inc (GNCA) Stock Getting a Bearish Rating

Monday, January 03, 2022 11:19 AM | InvestorsObserver Analysts

Mentioned in this article

Overall market sentiment has been down on Genocea Biosciences Inc (GNCA) stock lately. GNCA receives a Bearish rating from InvestorsObserver Stock Sentiment Indicator.

Genocea Biosciences Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on GNCA!
See Full GNCA Report

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With GNCA Stock Today?

Genocea Biosciences Inc (GNCA) stock is unmoved 0% while the S&P 500 has risen 0.13% as of 10:54 AM on Monday, Jan 3. GNCA is unchanged $0.00 from the previous closing price of $1.16 on volume of 78,489 shares. Over the past year the S&P 500 is higher by 28.96% while GNCA is lower by -50.64%. GNCA lost -$0.58 per share in the over the last 12 months. To screen for more stocks like Genocea Biosciences Inc click here.

More About Genocea Biosciences Inc

Genocea Biosciences Inc is a US-based biopharmaceutical company which is engaged in developing novel vaccines and immunotherapies to address diseases with significant unmet needs. Its product candidate includes GEN-003 which is an immunotherapy for the treatment of genital herpes as well as it owns pre-clinical immuno-oncology program focused on personalized cancer vaccines. The company focuses on developing vaccines and immunotherapies for unmet needs through its AnTigen Lead Acquisition System, which is used to design vaccines and immunotherapies. Genocea operates its business through the single segment being Developing and Commercializing vaccines. Click Here to get the full Stock Report for Genocea Biosciences Inc stock.

Share this article:

Related Articles